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Comparison of the efﬁcacy and safety of azilsartan
with that of candesartan cilexetil in Japanese patients
with grade I–II essential hypertension: a randomized,
double-blind clinical study
Hiromi Rakugi1, Kazuaki Enya2, Kenkichi Sugiura2 and Yoshinori Ikeda2
Azilsartan is a novel angiotensin receptor blocker being developed for hypertension treatment. This 16-week, multicenter,
randomized, double-blind study compared the efﬁcacy and safety of azilsartan (20–40mg once daily by forced titration) and
its ability to provide 24-h blood pressure (BP) control, with that of candesartan cilexetil (candesartan; 8–12mg once daily by
forced titration) in 622 Japanese patients with grade I–II essential hypertension. Efﬁcacy was evaluated by clinic-measured
sitting BP, and by ambulatory BP monitoring (ABPM) at week 14. Participants (mean age: 57 years, 61% males) had a mean
baseline sitting BP of 159.8/100.4mmHg. The mean change from baseline in sitting diastolic BP at week 16 (primary
endpoint) was  12.4mmHg in the azilsartan group and  9.8mmHg in the candesartan group, demonstrating a statistically
signiﬁcant greater reduction with azilsartan vs. candesartan (difference:  2.6mmHg, 95% conﬁdence interval (CI):  4.08 to
 1.22mmHg, P¼0.0003). The week 16 (secondary endpoint) mean change from baseline in sitting systolic BP was
 21.8mmHg and  17.5mmHg, respectively, a signiﬁcant decrease with azilsartan vs. candesartan (difference:  4.4mmHg,
95% CI:  6.53 to  2.20mmHg, Po0.0001). On ABPM, the week 14 mean changes from baseline in diastolic and systolic
BP were also signiﬁcantly greater with azilsartan over a 24-h period, and during the daytime, night-time and early morning.
Safety and tolerability were similar among the two groups. These data demonstrate that once-daily azilsartan provides a more
potent 24-h sustained antihypertensive effect than that of candesartan but with equivalent safety.
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INTRODUCTION
Hypertension is a primary risk factor for cardiovascular disease, and
strict blood pressure (BP) control is critical from the standpoint of
prevention of cardiovascular disease.1 In Japan, where the number of
people with hypertension is approximately 40 million, it is estimated
that around 50% of patients on antihypertensive treatment are
inadequately managed in terms of their ofﬁce BP, highlighting the
need for stricter BP control to prevent adverse sequelae.2,3 Strict BP
control over 24h, including the night-time and early morning hours,
is crucial, as the average BP level over 24h, nocturnal and early
morning BP are more closely associated with target organ damage and
cardiovascular events than ofﬁce BP.4–6 In clinical practice, however, it
is not infrequent that existing antihypertensive drugs fail to provide an
adequate antihypertensive effect that is sustained over 24h.7 In the
J-MORE (Jichi Morning Hypertension Research) study, 60.7% of
treated hypertensives with well-controlled clinic BP were found to
have masked morning hypertension (systolic BP (SBP) X135mmHg;
diastolic BP (DBP) X85mmHg), and only 16.4% of patients
overall had well-controlled clinic and morning BP levels.8 These
ﬁndings may be related to the limited BP-lowering effect and duration
of action of some antihypertensives, highlighting the importance of
treatments that control BP over a full 24-h period when administered
once daily.
The current Japanese Society of Hypertension Guidelines for
the Management of Hypertension2 advocate the use of ﬁve classes
of drugs as ﬁrst-line treatments for hypertension: calcium channel
blockers, angiotensin II (AII) receptor blockers (ARBs),
angiotensin-converting enzyme (ACE) inhibitors, diuretics and
b-adrenoceptor blockers (b-blockers). Among the recommended
ﬁrst-line agents, the ARBs are now widely used as a key component
of antihypertensive regimens because of their favorable efﬁcacy/
tolerability proﬁles.9 In addition, clinical outcome trials have shown
that the ARBs reduce the proportion of hypertensive patients who
develop type 2 diabetes mellitus,10 and improve cardiovascular outcomes
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diabetic kidney disease.15,16
Azilsartan is a new ARB that inhibits the binding of AII to AII
type 1 (AT1) receptors selectively, and is thus expected to exert a more
potent and sustained BP-lowering effect than existing ARBs. In an
in vitro study, azilsartan was shown to have a higher afﬁnity for and
slower dissociation from AT1 receptors than other ARBs (olmesartan,
telmisartan, valsartan and irbesartan).17 The present study was designed
to compare the efﬁcacy and tolerability of azilsartan 20–40mg once
daily with candesartan cilexetil (the most commonly used ARB in
Japan) 8–12mg once daily (the most frequently used dosage and
maximum clinically approved dosage in Japan) in patients with
grade I or II essential hypertension. The study also evaluated
the ability of these drugs to provide 24-h BP control using ambulatory
BP monitoring (ABPM).
METHODS
Study design
This was a phase III, randomized, double-blind, parallel-group study compar-
ing the efﬁcacy and safety of azilsartan and candesartan cilexetil (candesartan)
in Japanese patients with grade I or II essential hypertension. In addition, the
persistence of the effect of azilsartan, measured by ABPM, was assessed. The
study was conducted at 33 centers in Japan between May 2009 and June 2010.
After a 4-week single-blind, placebo run-in period, eligible patients were
randomized equally (via an interactive web response system) to receive either
azilsartan or candesartan in a double-blinded manner using plasma renin
activity (o0.5ngml 1 per h or X0.5ngml 1 per h) at week  2a sa
stratiﬁcation factor for randomization. During the 16-week, double-blind
treatment period, all patients in each group received the assigned study drug
once daily before or after breakfast. Patients in the azilsartan group received a
dosage of 20mg daily for the ﬁrst 8 weeks and then 40mg daily for the
subsequent 8 weeks. Patients in the candesartan group received a dosage of
8mg daily for the ﬁrst 8 weeks and then 12mg daily for the subsequent 8 weeks.
The study was approved by Institutional Review Boards at each study center,
and was conducted in accordance with the ethical provisions set out in the
Declaration of Helsinki, the International Conference on Harmonisation,
Harmonised Tripartite Guideline for GCP (Good Clinical Practice) E6(R1)
and all applicable local laws and regulations. All patients were required to provide
written informed consent prior to the initiation of any study-related procedures.
The trial was registered with the Japan Pharmaceutical Information Center
Clinical Trials Information (JapicCTI) at http://www.clinicaltrials.jp/user/cte_
main_e.jsp (identiﬁer JapicCTI-090762).
Patients
Patients with a diagnosis of grade I or II essential hypertension were assessed
during the single-blind, placebo run-in period. To be eligible for the study,
patients were required to be X20 years of age and have a sitting DBP of X95
and o110mmHg, and a sitting SBP of X150 and o180mmHg at weeks  2
and 0 of the run-in period. Women of child-bearing potential were required to
practice effective contraception during the course of the study. Exclusion
criteria were grade III hypertension (BP X180/X110mmHg), secondary or
malignant hypertension; the presence of cardiovascular disease; a 48mmHg
decrease in DBP from week  2 to week 0; signiﬁcant hepatic or renal disease;
hyperkalemia; malignancy; known hypersensitivity to ARBs, ACE inhibitors or
direct renin inhibitors; a history of drug or alcohol abuse within the previous
2 years; a day–night reversal lifestyle; and pregnancy or lactation. Other
medications not permitted during the study period were antihypertensive and
antianginal drugs, hypnosedative/antianxiety agents, antidepressants, non-ster-
oidal anti-inﬂammatory drugs, glucocorticoids, liquorice preparations, antiar-
rhythmic drugs, estrogens, digitalis preparations and potassium supplements.
Study procedures
Patients were assessed via measurements of sitting BP and pulse rate and via
physical examinations at clinic visits every 2 weeks during both the 4-week
placebo run-in period and the 16-week treatment period. Sitting BP was
measured by the investigator at least three times at 1- or 2-minute intervals
at trough (24±3h post-dose) using a digital or manual BP monitor, and the
mean value of two stable consecutive BP measurements was used for analysis.
ABPM, in which BP was measured at 30-minute intervals for X26h using an
oscillometric monitor (TM- 2431, A&D), was undertaken at baseline (week 0)
and at week 14, starting at 1000 hours (±1h). Patients took the study drug
X1h after the start of the measurements in the morning, and after the
completion of measurements on the following day. During the period of
ABPM, patients were instructed to avoid taking a bath, taking an afternoon
nap, performing exercise and consuming alcohol- and caffeine-containing
food/drinks. The major quality criteria used for an acceptable ABPM recording
included the following: (1) minimum of 80% of the BP readings expected
during the 24-h period; (2) no more than 2 nonconsecutive hours with o1
valid BP reading; and (3) no behaviors seriously affecting BP (afternoon nap,
drinking and so on).
With regard to adverse events, all patients were queried at every visit with
non-leading questions. In addition, a resting 12-lead electrocardiogram was
performed at baseline and week 16. Clinical laboratory tests (hematology,
serum chemistry, urinalysis) were performed at weeks  4, 0 (baseline), 2, 8 and
16 after the patients had fasted for X10h.
Outcome criteria
The primary efﬁcacy endpoint was the change from baseline in the sitting
trough (pre-dose) DBP at the end of the treatment period (week 16), using last
observation carried forward (LOCF) data analysis. Secondary efﬁcacy endpoints
included: (1) the changes from baseline to week 8 (before dose escalation) in
sitting trough DBP (LOCF analysis) and from baseline to weeks 8 (before dose
escalation) and 16 in sitting trough SBP (LOCF analysis); (2) sitting trough SBP
and DBP at each scheduled 2-week measurement time point; (3) the proportions
of responders (X20mmHg decrease in sitting trough SBP and X10mmHg
decrease in sitting trough DBP, or a sitting trough SBP of o130mmHg and a
sitting trough DBPof o85mmHg) and well-controlled patients (sitting trough
SBP o130mmHg and sitting trough DBP o85mmHg); (4) mean changes in
DBP and SBP on ABPM over a 24-h period, during both the daytime (while
awake) and night-time (while asleep). Safety was evaluated via the occurrence
of adverse events, clinical laboratory tests, vital signs, body weight and resting
12-lead electrocardiogram ﬁndings.
Statistical analysis
Sample size. The sample size was determined on the basis of the results of an
earlier dose-ranging study in Japanese patients (unpublished data; Takeda
Pharmaceutical Company). The difference in the mean change of sitting trough
DBP from baseline to the end of the treatment period between azilsartan 40mg
and candesartan 12mg (azilsartan group   candesartan group) was assumed to
be  2.5mmHg, with a s.d. common to all groups of 11.0mmHg. A sample
size of 305 subjects per group was required to verify the statistical difference
between azilsartan 40mg and candesartan 12mg with at least an 80% power
and a two-sided signiﬁcance level of 5%. Accordingly, the number of subjects
evaluable for the primary endpoint was determined to be 305 per group, or 610
in total.
Analysis of endpoints. The efﬁcacy analysis was performed in the full analysis
set, which included patients who were randomized and received the study
medications at least once. Safety was analyzed in the safety analysis set, which
included patients who received study medication at least once.
For the primary efﬁcacy endpoint, summary statistics and two-sided 95%
conﬁdence intervals (CI) of the meanvalues were determined and a one-sample
t-test was performed. The point estimate of the least-square (LS) mean and its
two-sided 95% CI for each treatment group were calculated using a two-way
analysis of variance model with the change from baseline (week 0) in the sitting
trough DBP at week 16 (LOCF data) as a dependent variable, and the plasma
renin activity (o0.5ngml 1 per h or X0.5ngml 1 per h) at week  2a n d
treatment group as independent variables. The same model was used to
calculate the point estimate of the difference in LS means between the azilsartan
and candesartan groups and its two-sided 95% CI.
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DBP between the two drugs in this study was set at 1.6mmHg as this value
was one-third of the placebo-adjusted treatment effect of candesartan 8mg on
sitting trough DBP in the dose-ranging study in Japanese patients (unpublished
data; Takeda Pharmaceutical Company), and because the results of the
secondary efﬁcacy endpoint in the present study (the change in the sitting
trough DBP at week 8 of treatment) were interpreted the same way as for the
primary endpoint. Azilsartan was regarded as non-inferior to candesartan if the
upper limit of the two-sided 95% CI of the difference in the estimated LS
means between the azilsartan and candesartan groups was below 1.6mmHg;
and superior to candesartan if the upper limit of the two-sided 95% CI was
below 1.6mmHg. The difference between azilsartan and candesartan was
regarded as statistically signiﬁcant if the upper limit of the two-sided 95% CI
was below zero.
Secondary efﬁcacy endpoints were analyzed similarly to the primary efﬁcacy
endpoint except for the proportions of responders and well-controlled patients,
the data for which were summarized by treatment group and compared at each
time point using the Cochrane-Mantel-Haenszel test with the plasma renin
activity at week  2 as a stratiﬁcation factor. For the ABPM endpoints, that is,
the changes from baseline in the mean DBP, SBP and pulse rate over 24h
(deﬁned as midday on day 1 of measurement to 1159 hours on day 2), during
the daytime/waking hours (midday on day 1 to 1min before bedtime and from
wake-up time to 1159 hours on day 2), and at night-time (bedtime to 1min
before waking), summary statistics and two-sided 95% CIs of the mean values
were presented by treatment group and by period and a one-sample t-test was
performed. ANCOVA was also performed using the plasma renin activity
(o0.5ngml 1 per h or X0.5ngml 1 per h) at week  2a n dt h et r e a t m e n t
group as independent variables, and baseline values as covariates.
RESULTS
Patients disposition and demographics
A total of 1022 patients provided informed consent for participation
in the trial, of whom 636 were randomized, 319 to azilsartan and 317
to candesartan (Figure 1); however, of the 636 randomized patients,
1 patient in the candesartan group did not receive treatment because
of a GCP violation at the study site. Of the 635 patients who were
treated, 587 (92.4%) completed the study (azilsartan 293; candesartan
294). The most common reasons for withdrawal were lack of efﬁcacy,
pretreatment event/adverse event and voluntary withdrawal (Figure 1).
There was no difference between the treatment groups in the percen-
tage of patients who were withdrawn.
Due to a major violation of GCP (conducted by a non-contracted
physician), at one of the study sites, which resulted in the exclusion of
6 patients who received azilsartan and 7 who received candesartan, the
full analysis set comprised 622 patients, 313 of whom received
azilsartan and 309 candesartan.
There were no remarkable differences between the treatment
groups at baseline for any demographic characteristic (Table 1). The
mean age of patients was 57 years in both treatment groups; males
accounted for 59% of the azilsartan group and 63% of the candesartan
group. The baseline mean sitting and 24-h BPs were 159.8/
100.4mmHg and 155.0/94.6mmHg, respectively, and the mean
plasma renin activity at week 2 was 0.6ngml 1 per h in both groups.
Treatment compliance was between 90% and 100% in X99% of
patients in both groups.
Changes in sitting BP levels
For the primary efﬁcacy parameter, the mean change from baseline in
sitting trough DBP at week 16 in the full analysis set, both azilsartan
and candesartan produced signiﬁcant decreases (azilsartan:  12.4±
9.87mmHg, candesartan:  9.8±8.50mmHg). The difference in the
LS means between the azilsartan and the candesartan groups was
 2.6mmHg (95% CI  4.08,  1.22). The upper limit of the 95% CI
fell below zero, meaning that the decrease was statistically signiﬁcantly
greater in the azilsartan group than in the candesartan group
(P¼0.0003) (Figure 2). For the secondary efﬁcacy variable, the mean
change in sitting trough SBP at week 16 was  21.8mmHg and
 17.5mmHg in the azilsartan and candesartan groups, respectively,
resulting in a signiﬁcant decrease in the azilsartan group compared
with the candesartan group (LS mean difference  4.4mmHg, 95% CI
 6.53,  2.20; Po0.0001). Similarly, the mean changes in sitting
trough DBP and in sitting trough SBP at week 8 (before
dose escalation) were signiﬁcantly greater with azilsartan than with
candesartan for each variable (Figure 2).
SBP and DBP at each scheduled measurement time point. With both
ARBs, the mean sitting trough DBP and SBP were signiﬁcantly
decreased from baseline at all scheduled time points from week 2 to
week 16 (data not shown). Signiﬁcantly greater reductions in the sitting
trough DBP and SBP were recorded in the azilsartan group in com-
parison with the candesartan group at all measurement time points.
The differences in LS means between the azilsartan and candesartan
groups ranged from  1.2mmHg to  2.8mmHg for DBP, and
from  2.3mmHg to  5.1mmHg for SBP. Sitting trough DBP and
SBP were signiﬁcantly decreased from the day of the dose increase
at week 8 in the azilsartan group at every scheduled measurement
time point.
Proportions of responders and well-controlled patients. As shown in
Table 2, the proportions of responders at week 16 (LOCF) and week 8
(LOCF) were signiﬁcantly higher in the azilsartan group (51.8%
and 44.1%, respectively) than in the candesartan group (34.3%
and 29.4%, respectively) (Po0.0001 and P¼0.0001, respectively).
Similarly, the proportions of well-controlled patients at week 16
(LOCF) and week 8 (LOCF) were also signiﬁcantly higher in the
azilsartan group (19.3% and 18.0%, respectively) than in the
candesartan group (13.3% and 10.0%, respectively) (P¼0.0409
and P¼0.0041, respectively).
Completed study (n = 293)
Withdrawn (n = 26)
- Lack of efficacy (n = 8)
- Pretreatment event/adverse
event (n = 5)
- Voluntary withdrawal (n = 2) 
- Major protocol deviation (n = 1)
- Other (n = 10) 
Completed study (n = 294
Withdrawn (n = 22)
- Lack of efficacy (n = 5)
- Pretreatment event/adverse
event (n = 4)
- Voluntary withdrawal (n = 2)
- Other (n = 11)
Azilsartan
20-40 mg od
(n = 319)
Patients providing informed
consent (n = 1022) Not randomized  (n = 386)
- Did not meet entrance criteria
(n = 312)
- Voluntary withdrawal (n = 17)
- Pretreatment event/adverse
event (n = 7)
- Other (n = 50) Randomized to treatment
(n = 636)
Candesartan
8-12 mg od
(n = 316)
Received double-blind study
medication  (n = 635)
Not treated (n = 1)
Figure 1 Disposition of patients in the study.
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achieved a sitting trough SBP of o140mmHg and a sitting trough
DBP of o90mmHg were 48.6% and 33.3% at week 16 (LOCF), and
38.9% and 29.4% at week 8 (LOCF) in the azilsartan and candesartan
groups, respectively.
Evaluations by ABPM
Reductions from baseline to week 14 in mean DBP and SBP during
ABPM were generally greater in the azilsartan group than in the
candesartan group, as shown by the 24-h proﬁles for time-matched
changes (Figure 3). The mean reductions from baseline to week 14 in
the 24-h, daytime and night-time mean DBP and SBP during ABPM
were all signiﬁcantly greater in the azilsartan group than in the
candesartan group (Table 2). For mean DBP, the differences in LS
means between the azilsartan and candesartan groups were  2.1mmHg,
95% CI  3.29,  0.89, P¼0.0007 during 24h;  2.5mmHg, 95% CI
 3.83,  1.22, P¼0.0002 in the daytime; and  1.5mmHg, 95% CI
 2.92,  0.10, P¼0.0364 at night-time. For mean SBP, the differences
in LS means were  3.7mmHg, 95% CI  5.70,  1.62, P¼0.0005
during 24h;  4.4mmHg, 95% CI  6.63,  2.20, P¼0.0001 in the
daytime; and  2.9mmHg, 95% CI  5.22,  0.61, P¼0.0133 at night-
time. Although the early morning mean SBP (deﬁned as the average
SBP during the ﬁrst 2-h period after awakening) was not a preplanned
study endpoint, the decrease in this parameter from baseline to week
14 was also signiﬁcantly greater in the azilsartan group than in the
candesartan group ( 4.4mmHg, 95% CI  7.31,  1.42, P¼0.0038).
In addition, trough-to-peak ratios (not a preplanned study endpoint)
on ABPMat week 14 were 0.97 and 0.75 for DBPand 0.95 and 0.82 for
SBP in the azilsartan and candesartan groups, respectively (Table 2).
The trough value was deﬁned as the mean change in BP during 2h of
premedication on day 2; the peak value was deﬁned as the mean
change in BP between the time the BP change was maximal (2–10h
after study drug intake on day 1) and just after that.18
Subgroup analyses
Mean changes from baseline in sitting trough DBPand SBP at week 16
(LOCF) were investigated in the full analysis set subgroups stratiﬁed
by baseline characteristics, including sitting DBP (week 0), sitting SBP
(week 0), gender, body weight, body mass index, age, plasma renin
activity, eGFR and the presence or absence of diabetes mellitus. In
both treatment groups, the mean decrease from baseline (week 0) in
sitting trough DBP and SBP tended to be greater in patients with high
plasma renin activity (X0.5ngml 1 per h) than in subjects with low
plasma renin activity (o0.5ngml 1 per h). Independently of plasma
renin activity, the mean decrease from baseline (week 0) in sitting
trough DBP and SBP at week 16 (LOCF) was greater in the azilsartan
group than in the candesartan group in all other subgroups (see
Supplementary Information).
Table 1 Baseline demographic characteristics of 622 patients with grade I–II hypertension randomized to treatment (FAS populations)
Characteristic Azilsartan (n¼313) Candesartan (n¼309) Total (n¼622)
Age, years 57.0 (± 9.69) 56.9 (± 10.00) 56.9 (± 9.84)
Gender:
Male 184 (58.8%) 196 (63.4%) 380 (61.1%)
Female 129 (41.2%) 113 (36.6%) 242 (38.9%)
Weight, kg 67.7 (± 12.18) 68.6 (± 14.17) 68.2 (± 13.20)
BMI, kgm 2 25.6 (± 4.09) 25.5 (± 3.88) 25.5 (± 3.98)
Duration of hypertension, years 8.7 (± 7.79) 7.9 (± 7.60) 8.3 (± 7.70)
Sitting BP, mmHg:
DBP 100.3 (± 4.26) 100.4 (± 4.11) 100.4 (± 4.19)
SBP 160.0 (± 7.70) 159.6 (± 7.27) 159.8 (± 7.48)
ABPM values, mmHg:
24-h mean DBP 94.6 (± 9.79) 94.6 (± 9.53) 94.6 (± 9.65)
Daytime mean DBP 98.5 (± 10.20) 98.1 (± 9.80) 98.3 (± 10.00)
Night-time mean DBP 86.5 (± 11.21) 87.1 (± 10.52) 86.8 (± 10.86)
24-h mean SBP 155.2 (± 13.97) 154.9 (± 13.64) 155.0 (± 13.80)
Daytime mean SBP 160.7 (± 14.05) 159.9 (± 13.91) 160.3 (± 13.98)
Night-time mean SBP 143.6 (± 17.65) 143.9 (± 16.51) 143.7 (± 17.08)
Early morning mean SBP 160.7 (± 16.57) 159.5 (± 15.62) —
Plasma renin activity, ngml 1 per h 0.61 (± 0.529) 0.60 (± 0.598) 0.61 (± 0.564)
eGFR, mlmin 1 per 1.73m2 77.0 (± 14.16) 76.8 (± 14.59) 76.9 (± 14.37)
Concurrent medical conditionsa:
Dyslipidemia 182 (58.1%) 168 (54.4%) 350 (56.3%)
Diabetes mellitus 61 (19.5%) 73 (23.6%) 134 (21.5%)
Medication history:
Antihypertensivesb 241 (77.0%) 230 (74.4%) 471 (75.7%)
Abbreviations: ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate;
FAS, full analysis set; SBP, systolic blood pressure.
aMost frequent concomitant conditions.
bIncluding calcium channel blockers (56.8% of patients), ARBs (45.7%), diuretics (8.0%), ACE inhibitors (4.5%), b-blockers (4.5%), and a-blockers (1.1%).
Values are means±s.d. or number (%).
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The study drugs were equally well tolerated and there were no
clear differences in the incidences of treatment-emergent adverse
events (TEAEs) between the two treatment groups. TEAEs were
reported by 58.1% of patients (182/313) who received azilsartan and
52.4% (162/309) who received candesartan (Table 3). The vast
majority of TEAEs were either mild or moderate in intensity in the
two groups (181 of 182 in the azilsartan group; 160 of 162 in the
candesartan group). No clear trend of time- or dose-dependency in
the incidence of TEAEs was evident in either treatment group (data
not shown). No deaths occurred during the study. Discontinuations
due to adverse events and serious adverse events were infrequent
in both groups.
The most common TEAEs occurring in 3% or more of the patients
in the azilsartan group were nasopharyngitis (18.8% in the azilsartan
group vs. 16.2% in the candesartan group), upper respiratory tract
inﬂammation (5.1% vs. 4.2%, respectively), and pharyngitis (3.2% vs.
2.3%, respectively). The overall incidence of hypotension-related events
(dizziness, dizziness postural, syncope, vertigo and vertigo positional)
was comparable to the two drugs— 11 of 313 patients (3.5%) who
received azilsartan as compared with 10 of 309 patients (3.2%) who
received candesartan. Syncope was reported in one patient in the
candesartan group.
Adverse events considered treatment-related were infrequent in
both groups, but were slightly more common with azilsartan than
with candesartan (7.3% vs. 1.9%; Table 3). This was mainly due to
slightly higher incidences of postural dizziness (1.6% vs. 0.3%) and
increased blood uric acid levels (1.6% vs. 0%), although they were
infrequent and were not of clinical concern as they did not lead to
syncope or gout.
There were no remarkable ﬁndings of clinical concern in laboratory
test results, vital signs, body weight and 12-lead electrocardiogram
ﬁndings.
DISCUSSION
The ﬁndings of the study showed that azilsartan (20–40mg once daily)
provided a signiﬁcantly greater reduction from baseline of clinic-
measured BP (both sitting trough SBP and sitting trough DBP) than
candesartan (8–12mg once daily) in Japanese patients with grade I–II
essential hypertension at all time points from weeks 2 to 16 over the
treatment period. In addition, the proportions of clinical responders
and patients who were categorized as well-controlled at weeks 8 and
Change from baseline in sitting SBP at weeks 8 and 16
−2.6 (95% CI −4.08, − 1.22)
P = 0.0003
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Figure 2 Changes (least-square (LS) means) in sitting trough diastolic
blood pressure (DBP) and systolic blood pressure (SBP) from baseline
(week 0) to weeks 8 (before dose escalation) and 16 in the azilsartan and
candesartan treatment groups (full analysis set populations; last observation
carried forward (LOCF) analysis). LS mean differences between the groups
and 95% conﬁdence intervals (CIs) and P-values for the differences are
shown (two-way analysis of variance model using plasma renin activity at
week  2 and treatment group as independent variables). *Primary efﬁcacy
endpoint.
Table 2 Proportions of patients who were responders and whose BP
was well-controlled by azilsartan and candesartan at weeks 8 and 16,
and changes in ABPM values from baseline to week 14 in the two
treatment groups (FAS populations)
Parameter
Azilsartan
(n¼311)
Candesartan
(n¼309) P-value
Sitting trough BP levels:
Respondersa (LOCF analysis), n (%)
Week 8 137 (44.1%) 91 (29.4%) 0.0001b
Week 16 161 (51.8%) 106 (34.3%) o0.0001b
Well-controlled patients (LOCF analysis), n (%)
Week 8 56 (18.0%)c 31 (10.0%)c 0.0041b
121 (38.9%)d 91 (29.4%)d —
Week 16 60 (19.3%)c 41 (13.3%)c 0.0409b
151 (48.6%)d 103 (33.3%)d —
ABPM values:
Changes from baseline to week 14, mmHg (mean±s.d.)e
24-h mean DBP  7.6 (± 8.66)  5.5 (± 7.05) 0.0007f
Daytime mean DBP  7.3 (± 9.44)  4.7 (± 7.88) 0.0002f
Night-time mean DBP  8.3 (± 9.86)  7.1 (± 8.43) 0.0364f
24-h mean SBP  13.0 (± 14.30)  9.4 (± 11.46) 0.0005f
Daytime mean SBP  12.1 (± 15.52)  7.6 (± 12.68) 0.0001f
Night-time mean SBP  15.3 (± 16.25)  12.6 (± 13.52) 0.0133f
Early morning mean SBP  12.2 (± 20.94)  7.4 (± 15.85) 0.0038f
Trough-to-peak ratios at week 14
DBP 0.97 0.75 —
SBP 0.95 0.82 —
Abbreviations: ABPM, ambulatory blood pressure monitoring; ANCOVA, analysis of covariance;
DBP, diastolic blood pressure; FAS, full analysis set; LOCF, last observation carried forward;
SBP, systolic blood pressure.
aPatients who had a X20mmHg decrease in sitting trough SBP and a X10mmHg decrease in
sitting trough DBP, or who had a sitting trough SBP of o130mmHg and a sitting trough DBP
of o85mmHg.
bP-values determined by the Cochran–Mantel–Haenszel test, stratiﬁed by plasma renin activity.
cPatients who had a sitting trough SBP of o130mmHg and a sitting trough DBP of
o85mmHg.
dPatients who had a sitting trough SBP of o140mmHg and a sitting trough DBP of
o90mmHg.
eABPM values at 14 weeks were not recorded for some patients (n¼273 in the azilsartan group;
n¼275 in the candesartan group).
fP-values for differences in LS means (ANCOVA model).
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Hypertension Research16 were signiﬁcantly higher in the azilsartan group than in the
candesartan group. When the time-courses of BP changes with two
ARBs were evaluated by ABPM at 14 weeks, azilsartan was also found
to provide a signiﬁcantly greater reduction from baseline in mean SBP
and DBP than candesartan during the 24-h time period, as well as in
the daytime during waking hours, at night-time during sleep, and in
the early morning (SBP), indicating a more sustained duration of
action. Moreover, trough-to-peak ratios for both DBP and SBP on
ABPM at week 14 of treatment were higher in the azilsartan group
than in the candesartan group, providing further evidence of a longer
duration of action of azilsartan relative to candesartan.19
The longer duration of antihypertensive efﬁcacy of azilsartan was
not at the expense of diminished tolerability, as the two ARBs were
equally well tolerated in this study. The majority of TEAEs were mild
in severity, and the most commonly reported events with both drugs
were nasopharyngitis, upper respiratory tract inﬂammation and
pharyngitis. There was a slightly higher incidence of treatment-related
AEs with azilsartan thanwith candesartan (7.3% vs. 1.9%), mainly as a
result of slightly higher incidences of postural dizziness (1.6% vs.
0.3%) and increased blood uric acid levels (1.6% vs. 0%). However,
these events were generally of mild intensity and resolved without
intervention and, importantly, were not of clinical concern as they did
not lead to syncope or gout. Overall, treatment-related AEs were
infrequent in the two groups. There was no clear trend of time- or
dose-dependency in the incidence of TEAEs with either treatment,
and there were no remarkable ﬁndings of clinical concern in labora-
tory test results, vital signs, body weight and 12-lead electrocardio-
gram ﬁndings.
Earlier clinical trials conducted outside of Japan that compared
azilsartan medoxomil (a prodrug of azilsartan that is rapidly converted
to the active form, azilsartan, during the absorption phase) with other
ARBs, have reported similar ﬁndings to our study. In a multicenter,
randomized, double-blind study that compared azilsartan medoxomil
and olmesartan medoxomil in US patients with primary hypertension,
azilsartan medoxomil was signiﬁcantly more effective in lowering
mean 24-h SBP than olmesartan medoxomil.20 Similarly, in a multi-
center, randomized, double-blind study in patients with grade I–II
hypertension conducted in Latin American countries and the USA,
treatment with azilsartan medoxomil was signiﬁcantly more effective
than valsartan and olmesartan in lowering mean 24-h SBP.21 In both
trials, the safety proﬁle of azilsartan medoxomil was similar to that of
the ARBs and the placebo with which it was compared.
The principal limitations of the present study were that only
patients with grade I or II essential hypertension (without cardiovas-
cular disease or signiﬁcant renal impairment) were eligible for enroll-
ment and the relatively short treatment duration, which preclude its
extrapolation to other categories of hypertensive patients and any
deﬁnitive conclusions regarding its target organ-protective effects.
However, with regard to target organ protection, the Japanese People’s
Health Promotion Campaign for the 21st Century (Healthy Japan
21)22 has estimated that a 2mmHg decrease in the national SBP level
would lead to a 6.4% decrease in the prevalence of stroke and a 5.4%
decrease in that of ischemic heart disease (IHD), as well as a decrease
of approximately 9000 in the number of deaths from stroke and
approximately 4000 in the number of deaths from IHD. Therefore, the
LS mean difference in SBP recorded in this study of  4.4mmHg
between the treatment groups after 16 weeks of treatment is likely to
be clinically relevant and would be expected to contribute to a
decrease in the morbidity and mortality rates related to cerebrovas-
cular disease and IHD. Moreover, as the average BP level over 24h,
nocturnal and early morning BP are reported to be more closely
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Figure 3 24-h proﬁles of changes in mean diastolic blood pressure (DBP)
and systolic blood pressure (SBP) from baseline (week 0) to week 8 in the
azilsartan and candesartan treatment groups (ambulatory blood pressure
monitoring (ABPM) data; full analysis set populations).
Table 3 Treatment-emergent adverse events (n, %) occurring in the
azilsartan and candesartan treatment groups (safety analysis sets)
Adverse event
Azilsartan
(n¼313)
Candesartan
(n¼309)
Patients experiencing at least 1 TEAE
(all-cause events):
182 (58.1%) 162 (52.4%)
Mild events 167 (53.4%) 145 (46.9%)
Moderate events 14 (4.5%) 15 (4.9%)
Severe events 1 (0.3%) 2 (0.6%)
Treatment-related TEAEsa 23 (7.3%) 6 (1.9%)
TEAEs leading to drug discontinuation 5 (1.6%) 4 (1.3%)
Serious TEAEs 1 (0.3%) 2 (0.6%)
Most common TEAEs:b
Nasopharyngitis 59 (18.8%) 50 (16.2%)
Upper respiratory tract inﬂammation 16 (5.1%) 13 (4.2%)
Pharyngitis 10 (3.2%) 7 (2.3%)
Gastroenteritis 9 (2.9%) 7 (2.3%)
Blood creatine phosphokinase increased 9 (2.9%) 10 (3.2%)
Seasonal allergy 8 (2.6%) 5 (1.6%)
Back pain 7 (2.2%) 6 (1.9%)
Blood triglycerides increased 7 (2.2%) 3 (1.0%)
Blood uric acid increased 7 (2.2%) 0
Abbreviation: TEAE, treatment-emergent adverse event.
aAdverse events for which involvement of the study medications was suspected by the
investigator.
bOccurring in X2% of patients in either treatment group.
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Hypertension Researchassociated with hypertensive target organ damage and cardiovascular
events than clinic-measured BP,4–6 the ﬁnding that azilsartan provided
a signiﬁcantly greater reduction from baseline to week 14 in mean SBP
and DBP than candesartan during a 24-h time period, as well as in the
daytime during waking hours, night-time hours during sleep, and in
the early morning (SBP) suggests that it provides greater protection
against cardiovascular events.
In conclusion, this study has shown that once-daily administration
of azilsartan produces a 24-h sustained antihypertensive effect that
is more potent than that of candesartan in Japanese patients with
grade I–II essential hypertension but at an equivalent level of safety.
Consequently, azilsartan administered once daily could provide higher
rates of hypertension control during a 24-h period (including the
night and early morning hours) and might be expected to give greater
protection against cardiovascular events in patients with essential
hypertension, although this remains to be proven in prospectively
designed clinical studies.
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